Health

FDA requires vision loss warning on GLP-1 drugs

On November 9, 2026, the FDA ordered a NAION warning on all GLP-1 drugs. What changes for doctors, clinics, pharmacies and patients in Mexico.

Plumas inyectables GLP-1 con advertencia NAION en refrigerador de farmacia

The U.S. Food and Drug Administration (FDA) ordered on November 9, 2026 that all GLP-1 receptor agonist drugs, the class that includes Ozempic, Wegovy, Mounjaro and Zepbound, carry a label warning about a rare risk of vision loss.

A meta-analysis of 126 trials with 134,253 patients, cited by the regulator, found 6.4 cases of non-arteritic anterior ischemic optic neuropathy (NAION) per 100,000 person-years among users, versus 3.8 among comparators. NAION reduces blood flow to the optic nerve and causes sudden, painless vision loss in one eye, often upon waking. The review stemmed from a 2024 JAMA Ophthalmology study that linked semaglutide to more cases, and the European Medicines Agency classified the risk as very rare in 2025, according to MedPage Today. In Mexico the issue is not new either: Cofepris issued a risk notice on May 28, 2024 over the indiscriminate use of semaglutide and liraglutide for weight loss. These drugs are prescribed in private practices, obesity clinics and telemedicine, where ophthalmological history is rarely recorded.

The warning goes in the Warnings and Precautions section and covers exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, tirzepatide and orforglipron, regardless of whether the use is for diabetes or obesity. FDA surveillance data, according to MedPage Today, show a higher risk versus DPP-4 inhibitors (hazard ratio 1.43, confidence interval 1.02 to 2.01) and no statistical difference versus SGLT-2 inhibitors (1.19, 0.91 to 1.54). The FDA did not identify a biological mechanism in animal studies and describes the association as potential, not causal. Its guidance is that patients report any sudden visual change in one eye immediately, that physicians refer them to ophthalmology, and that discontinuation be considered if NAION is diagnosed, without stopping the drug on their own.

For clinics, pharmacies and telemedicine platforms that prescribe or dispense these medications, the data leaves open how to document ophthalmological history during the consultation and how to explain a rare risk without alarming the patient. The open question is whether Cofepris will update the Mexican label on the same terms, and on what timeline.

This article was drafted with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.

Sources